Ciclosporin - Ocular Therapeutix
Alternative Names: Ciclosporin ophthalmic insert - Ocular Therapeutix; Cyclosporine intracanalicular insert - Ocular Therapeutix; OTX-CSI; OTX-CSI intracanalicular insert; Sustained release ciclosporin intracanalicular hydrogel insert - Ocular TherapeutixLatest Information Update: 21 Apr 2025
At a glance
- Originator Ocular Therapeutix
- Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Heart failure therapies; Neuroprotectants
- Mechanism of Action Calcineurin inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Suspended Dry eyes
Most Recent Events
- 31 Dec 2024 Suspended - Phase-II for Dry eyes in USA (Ophthalmic)
- 31 Mar 2023 Ocular Therapeutix plans a pivotal trial for Dry eyes (Opthalmic, Implant) in Q2 of 2023 (Ocular Therapeutix pipeline, March 2023)
- 22 Feb 2022 Ocular Therapeutix completes phase II portion of phase I/II trial in Dry eyes in USA (Ophthalmic) (NCT04362670)